Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2

Pandemic 2009 H1N1 influenza A virus (2009 H1N1) differs from H1N1 strains that circulated in the past 50 years, but resembles the A/New Jersey/1976 H1N1 strain used in the 1976 swine influenza vaccine. We investigated whether sera from persons immunized with the 1976 swine influenza or recent seasonal influenza vaccines, or both, neutralize 2009 H1N1. Using retroviral pseudovirions bearing hemagglutinins on their surface (HA-pseudotypes), we found that 77% of the sera collected in 1976 after immunization with the A/New Jersey/1976 H1N1 swine influenza vaccine neutralized 2009 H1N1. Forty five percent also neutralized A/New Caledonia/20/1999 H1N1, a strain used in seasonal influenza vaccines during the 2000/01–2006/07 seasons. Among adults aged 48–64 who received the swine influenza vaccine in 1976 and recent seasonal influenza vaccines during the 2004/05–2008/09 seasons, 83% had sera that neutralized 2009 H1N1. However, 68% of age-matched subjects who received the same seasonal influenza vaccines, but did not receive the 1976 swine influenza vaccine, also had sera that neutralized 2009 H1N1. Sera from both 1976 and contemporary cohorts frequently had cross-neutralizing antibodies to 2009 H1N1 and A/New Caledonia/20/1999 that mapped to hemagglutinin subunit 2 (HA2). A conservative mutation in HA2 corresponding to a residue in the A/Solomon Islands/3/2006 and A/Brisbane/59/2007 H1N1 strains that circulated in the 2006/07 and 2007/08 influenza seasons, respectively, abrogated this neutralization. These findings highlight a cross-neutralization determinant influenced by a point mutation in HA2 and suggest that HA2 may be evolving under direct or indirect immune pressure.

[1]  R. Webster,et al.  Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. , 2011, Vaccine.

[2]  Christopher L. Perdue,et al.  Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel , 2010, PloS one.

[3]  R. Porcher,et al.  Detection of Extensive Cross-Neutralization between Pandemic and Seasonal A/H1N1 Influenza Viruses Using a Pseudotype Neutralization Assay , 2010, PloS one.

[4]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[5]  Hong Sun,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009 .

[6]  I. Barr,et al.  Cross-Reactive Antibodies to Pandemic (H1N1) 2009 Virus, Singapore , 2010, Emerging infectious diseases.

[7]  W. Dowdle.  The 1976 Experience , 1997 .

[8]  I. Stephenson,et al.  Influenza vaccines for the future , 2009 .

[9]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[10]  Eduardo Lazcano-Ponce,et al.  Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City , 2009, BMJ : British Medical Journal.

[11]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[12]  Ryo Takano,et al.  A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. , 2010, Antiviral research.

[13]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[14]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[15]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[16]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[17]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[18]  R. Rappuoli,et al.  Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. , 2009, Vaccine.

[19]  R. Webby,et al.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. L. Montagne,et al.  Pandemic Influenza—Confronting a Reemergent Threat , 1997 .

[21]  T. Popović,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009, MMWR. Morbidity and mortality weekly report.

[22]  Hang Xie,et al.  Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. , 2010, Journal of virological methods.

[23]  Wei Wang,et al.  Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. , 2008, Journal of virological methods.

[24]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[25]  A. García-Sastre,et al.  Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines , 2010, PLoS pathogens.

[26]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[27]  J. Skehel,et al.  Refinement of the influenza virus hemagglutinin by simulated annealing. , 1991, Journal of molecular biology.

[28]  I. Wilson,et al.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation , 1981, Nature.

[29]  P. Kelly,et al.  Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. , 2010, Vaccine.

[30]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[31]  Kathryn L. Schornberg,et al.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. , 2008, Critical reviews in biochemistry and molecular biology.

[32]  I. Wilson,et al.  HIV-1 and influenza antibodies: seeing antigens in new ways , 2009, Nature Immunology.

[33]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[34]  F. Ennis,et al.  Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. , 1977, The Journal of infectious diseases.

[35]  W. Dowdle.  Pandemic influenza: confronting a re-emergent threat. The 1976 experience. , 1997, The Journal of infectious diseases.

[36]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[37]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[38]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[39]  J. Castelán-Vega,et al.  A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. , 2010, Virology.

[40]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[41]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[42]  H. Kelly,et al.  Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[43]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[44]  John Steel,et al.  Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries , 2010, PLoS pathogens.

[45]  J. Yewdell,et al.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) , 1982, Cell.

[46]  R. Weiss,et al.  A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies , 2007, Influenza and other respiratory viruses.